Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period.  “We feel […] Continue reading ->
Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population.  That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading ->
While the COVAX Facility, a global initiative to pool procurement of a safe and effective COVID-19 vaccine, has been gaining momentum, another global initiative to pool intellectual property rights for tools to combat the pandemic has been moving at a much slower pace. Only three more countries have signed on to support the COVID-19 Technology […] Continue reading ->
Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading ->
As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls.  Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading ->
The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading ->
Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading ->
Moderna, a frontrunner in the COVID-19 vaccine development race, today entered the final phase of testing required before pursuing regulatory approval, beginning the Phase III trial for their vaccine candidate mRNA-1273. The trial, titled COVE (Coronavirus Efficacy), will measure how well a 100 microgram dose of the vaccine can protect people against developing symptomatic COVID-19 […] Continue reading ->